Class Action Claims Patients Overpaid for Dementia-Treating Namenda IR Due to Drugmaker’s Anticompetitive ‘Scheme’
March 3, 2020 A proposed class action lawsuit alleges Forest Laboratories, LLC has engaged in an “anticompetitive scheme” through which the pharmaceutical company has been able to charge inflated prices for dementia drug Namenda IR.